Dyax Shares Rise As Rival Kos's Trials Inconclusive
Shares of Dyax Corp. (DYAX) gained more than 18% on the day on news from its rival Kos Pharmaceuticals (KOSP) that one of its two phase 3 clinical trials for its hereditary angioedema (HAE) drug candidate Icatibant was inconclusive.
Dyax's HAE candidate, DX-88 is also in late phase trials, but did recieve a regulatory letter from the FDA back in August seeking addiontal information. DX-88 is being developed with Genzyme (GENZ), and both companies expect regulatory approval of the drug in the second half of 2008.
Kos did announce however that despite the small setback in the Icatibant trials its partner, Jerini AG is still planning on submitting its approval application to the FDA by the end of this year, while also seeking an expedited review.
_
Shares of Dyax Corp. (DYAX) gained more than 18% on the day on news from its rival Kos Pharmaceuticals (KOSP) that one of its two phase 3 clinical trials for its hereditary angioedema (HAE) drug candidate Icatibant was inconclusive.
Dyax's HAE candidate, DX-88 is also in late phase trials, but did recieve a regulatory letter from the FDA back in August seeking addiontal information. DX-88 is being developed with Genzyme (GENZ), and both companies expect regulatory approval of the drug in the second half of 2008.
Kos did announce however that despite the small setback in the Icatibant trials its partner, Jerini AG is still planning on submitting its approval application to the FDA by the end of this year, while also seeking an expedited review.
_
posted by Nico at
5:32 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home